Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 22;12(23):7225.
doi: 10.3390/jcm12237225.

Evaluation of Femoropopliteal In-Stent Restenosis Characteristics Stratified by Stent Design

Elias Noory  1 , Tanja Böhme  1 , Jonas Salm  1 , Ulrich Beschorner  1 , Larissa Endress  2 , Roaa Bollenbacher  1 , Dirk Westermann  1 , Thomas Zeller  1
Affiliations

Evaluation of Femoropopliteal In-Stent Restenosis Characteristics Stratified by Stent Design

Elias Noory et al. J Clin Med. .

Abstract

Purpose: To evaluate the potential differences in characteristics of femoropopliteal in-stent restenosis (ISR) stratified by stent design with a focus on the swirling flow-inducing BioMimics 3D helical centerline stent.

Methods: Patients with ISR of the superficial femoral and popliteal arteries undergoing reintervention were included in this study. The primary endpoint was the angiographic localization and extent of restenosis or reocclusion with the following five different stent systems: SMART Control stent, Supera peripheral stent, GORE® VIABAHN® endoprosthesis, BioMimics 3D stent, and Zilver® PTX® stent.

Results: 414 ISR lesions were analyzed, affecting 236 Supera stents, 67 BioMimics 3D stents, 48 Zilver® PTX® stents, 38 SMART Control stents, and 25 VIABAHN® endoprostheses. The mean stent diameter and length were 5.7 ± 0.77 mm and 121.4 ± 94.8 mm, respectively. ISR included 310 (74.9%) lesions with 1 stent, 89 (21.5%) lesions with 2 stents, 14 (3.4%) lesions with 3 stents, and 1 lesion (0.2%) with 4 stents. Most lesions presented as reocclusions (67.4%) rather than focal (13.3%) or diffuse restenoses (19.3%). No significant differences in ISR lesion morphology were found. By trend, BioMimics 3D stent lesion extension was more focal (16.4% versus 12.7%, p = 0.258), with the highest proportion of lesions in which only the proximal stent third was affected (9.0% versus 5.8%, p = 0.230), as compared to the average of the other four devices. The occlusion rate was the second lowest for the BioMimics 3D stent (64.2 vs. 68.0%, p = 0.316). Risk factors for restenosis or occlusion were active smoking, pre-interventional occlusion, and popliteal intervention.

Conclusion: Our results suggest that the helical centerline stent design of the BioMimics 3D stent, which results in a swirling flow with increased wall shear stress, may offer protective properties over straight stent designs, including DES and endoprosthesis, regarding localization and extension of restenosis. Prospective, randomized studies are warranted.

Keywords: endovascular therapy; femoropopliteal artery; in-stent restenosis; peripheral artery disease; stent.

PubMed Disclaimer

Conflict of interest statement

Elias Noory: Honoraria received from: Bard-BD, Boston Scientific Corp, Abbott Vascular, Medtronic, ShockWave. Thomas Zeller: Honoraria received from: Abbott Vascular, Veryan, Biotronik, Boston Scientific Corp., Cook Medical, Gore & Associates, Medtronic, Philips-Spectranetics, Shockwave. Consulted for: Boston Scientific Corp., Gore & Associates, Medtronic, Veryan, Intact Vascular, Shockwave, Bayer, Vesper Medical. Research, clinical trial, or drug study funds received from (institution): 480 biomedical, Bard Peripheral Vascular, Veryan, Biotronik, Cook Medical, Gore & Associates, Medtronic, Philips, Terumo, TriReme, Shockwave, Med Alliance, Intact Vascular, B. Braun. Common stock: QT Medical. The other authors have no conflict of interest.

Figures

Figure 1
Figure 1
Study flow chart.
Figure 2
Figure 2
Fluoroscopy of stent designs in use. (A) BioMimics 3D stent, Veryan Medical Ltd., Galway, Ireland; (B) Supera peripheral stent, Abbott Vascular Corporation, Santa Clara, CA, USA; (C) Zilver® PTX®, Cook Medical, Bloomington, IN, USA; (D) GORE® VIABAHN® endoprosthesis, Gore & Associates Inc., Flagstaff, AZ, USA; (E) SMART Control stent, Cordis Endovascular, Fremont, CA, USA.
Figure 3
Figure 3
Kaplan–Meier curve for restenosis-free survival.
See this image and copyright information in PMC

References

    1. Bennett M.R., O’Sullivan M. Mechanisms of angioplasty and stent restenosis: Implications for design of rational therapy. Pharmacol. Ther. 2001;91:149–166. doi: 10.1016/S0163-7258(01)00153-X. - DOI - PubMed
    1. Minar E., Pokrajac B., Maca T., Ahmadi R., Fellner C., Mittlbock M., Seitz W., Wolfram R., Potter R. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angio-plasty: Results of a prospective randomized study. Circulation. 2000;102:2694–2699. doi: 10.1161/01.CIR.102.22.2694. - DOI - PubMed
    1. Stonebridge P.A., Hoskins P.R., Allan P.L., Belch J.F. Spiral laminar flow in vivo. Clin. Sci. 1996;91:17–21. doi: 10.1042/cs0910017. - DOI - PubMed
    1. Berry J.L., Santamarina A., Moore J.J.E., Roychowdhury S., Routh W.D. Experimental and computational flow evaluation of coronary stents. Ann. Biomed. Eng. 2000;28:386–398. doi: 10.1114/1.276. - DOI - PubMed
    1. Chen Z., Fan Y., Deng X., Xu Z. Swirling flow can suppress flow disturbances in endovascular stents: A numerical study. ASAIO J. 2009;55:543–549. doi: 10.1097/MAT.0b013e3181b78e46. - DOI - PubMed

LinkOut - more resources